1. Catalog
  2. Pride Webinar LGBTQ+ Health and Hepatology: Past, ...
Pride Webinar LGBTQ+ Health and Hepatology: Past, Present, and Future
Image For Activity Cover
Create Account
Availability
No future session
Cost
$0.00
Credit Offered
1 AMA PRA Category 1 Credit
1 Participation Credit
  • Description
  • Learning Objectives
  • Accreditation Information
  • Faculty and Disclosures
  • Recommended
This session explores the evolution of LGBTQ+ healthcare in hepatology through a past-present-future lens. It examines historical discrimination, current barriers faced by LGBTQ+ individuals in liver care, and strategies for creating a more inclusive and equitable healthcare environment. Attendees will gain insight into systemic biases, learn from community voices, and explore future-oriented solutions to improve outcomes and access for LGBTQ+ patients.
Upon completion of this course, participants should be able to:

• Describe historical barriers impacting LGBTQ+ liver health
• Identify current challenges and inclusive care practices
• Apply strategies to reduce disparities and support LGBTQ+ health equity

The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this blended (live and online) activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Aly Strauss, MD, PhD, MIE

Nothing to Disclose

Carl Streed, MD
Scientific Consultant/Advisor: Texas Health Instititute, L'Oreal

Chip Bowman, MD, MPH
Nothing to Disclose

Jess Wisocky, NP, MSN
Scientific Consultant/Advisor: Guidepoint Global Advisor

Howard Lee, MD:
Scientific Consultant/Advisor: AbbVie (has ended)

Martha Bausch, BSN, MSN

Staff:

Sally Cook, CMP, CHCP
Nothing to Disclose


Powered By